Please try another search
Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide. The company’s lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and antithrombotic properties. Its preclinical drug candidates comprise CS585 and CS014 that is in pre clinical stage for the treatment of cardiovascular diseases. The company has a collaboration agreement with the University of Michigan for the preclinical development program of CS585 and CS014, are preclinical drug candidate for cardiovascular diseases; and Abbott for use of CardioMEMS HF System. Cereno Scientific AB (publ) was founded in 2012 and is headquartered in Gothenburg, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Joakim Soderstrom | 40 | 2023 | Chairperson |
Sten R. Sorensen | 65 | 2015 | CEO & Director |
Gunnar Olsson | - | 2018 | Director & Member of Scientific Advisory Board |
Anders Svensson | 73 | 2018 | Director |
Faiez Zannad | - | - | Member of Scientific Advisory Board |
Raymond L. Benza | - | 2021 | Member of Scientific Advisory Board |
Gordon H. Williams | - | - | Member of Scientific Advisory Board |
Deepak L. Bhatt | 56 | - | Member of Scientific Advisory Board |
Jeppe Ovli Ovlesen | 62 | 2023 | Director |
Bertram Pitt | 92 | - | Chairman of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review